Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine

BACKGROUND: SARS‐CoV‐2 has spread worldwide causing more than 400 million people with virus infections since early 2020. Currently, the existing vaccines targeting the spike glycoprotein (S protein) of SARS‐CoV‐2 are facing great challenge from the infection of SARS‐CoV‐2 virus and its multiple S pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Weixu, Xiang, Yunru, Wu, Lianpeng, Chen, Zhuo, Li, Qingfeng, Chen, Jun, Guo, Yanru, Xia, Dandan, Chen, Na, Zhang, Lifang, Zhu, Shanli, Zhao, Kong‐Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169192/
https://www.ncbi.nlm.nih.gov/pubmed/35527696
http://dx.doi.org/10.1002/jcla.24479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169192/
https://www.ncbi.nlm.nih.gov/pubmed/35527696
http://dx.doi.org/10.1002/jcla.24479

Ejemplares similares